RxDoctor Payments Data

Amanda Schermer, DO

Family Medicine · Norton Shores, MINPI 1215428339

Payments from drug & device makers

$562in general payments, 2019–2025

Across 22 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$176
  • Pfizer$140
  • AstraZeneca$96
  • Boehringer Ingelheim$69
  • Amgen$31
  • Halozyme Inc$20
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$54397%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$562 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$29,761
Medicare patients
134
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$172,172
TrulicityDulaglutide68$102,526
OzempicSemaglutide63$100,394
MounjaroTirzepatide57$90,851
FarxigaDapagliflozin Propanediol51$59,061
XareltoRivaroxaban46$44,665
JardianceEmpagliflozin41$38,843
RexultiBrexpiprazole18$27,773
EntrestoSacubitril/Valsartan23$27,467
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$23,973
MyrbetriqMirabegron16$19,909
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$16,232
JanuviaSitagliptin Phosphate12$15,490
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$15,141
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$10,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$140$177,431164 claims
Novo NordiskOzempic$176$100,39463 claims
AstraZenecaFarxiga, Symbicort$96$66,92172 claims
Boehringer IngelheimJardiance, Stiolto Respimat$69$53,98468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Norton Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →